Stay updated on IMMU-132 Clinical Trial in Epithelial Cancer
Sign up to get notified when there's something new on the IMMU-132 Clinical Trial in Epithelial Cancer page.

Latest updates to the IMMU-132 Clinical Trial in Epithelial Cancer page
- Check3 days agoChange DetectedRevision: v3.6.6 replaces the previous v3.6.5 in the page footer. It indicates a minor platform update and does not change the study details on the page.SummaryDifference0.0%

- Check11 days agoChange Detected- A new publication citation was added to the Publications section: Sathe AG, Jones AK, Diderichsen PM, Wang X, Chang P, Verret W, Girish S. Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial. Clin Transl Sci. 2025 Jul;18(7):e70291. doi: 10.1111/cts.70291. This entry expands the study's referenced literature by including a 2025 pharmacokinetics analysis of Sacituzumab Govitecan in HR+/HER2- metastatic breast cancer.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, indicating a minor software update to the site. There is no change to the study content visible to users.SummaryDifference0.0%

- Check39 days agoChange DetectedThe revision history now shows Revision: v3.6.4 in place of Revision: v3.6.3.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3, indicating a new page version has been published. The change reflects minor administrative updates without modifying the study details.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page's revision tag was updated to v3.6.2, indicating a backend/template update with no visible content changes.SummaryDifference0.0%

Stay in the know with updates to IMMU-132 Clinical Trial in Epithelial Cancer
Enter your email address, and we'll notify you when there's something new on the IMMU-132 Clinical Trial in Epithelial Cancer page.